These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

867 related items for PubMed ID: 26966279

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis.
    Wu BJ, Shrestha S, Ong KL, Johns D, Dunn LL, Hou L, Barter PJ, Rye KA.
    Int J Cardiol; 2015 Nov 15; 199():204-12. PubMed ID: 26204569
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity.
    Guyard-Dangremont V, Lagrost L, Gambert P.
    J Lipid Res; 1994 Jun 15; 35(6):982-92. PubMed ID: 8077854
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency.
    Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer JR, Ishikawa T, Fairwell T, Zech LA, Nakamura H.
    J Clin Invest; 1993 Oct 15; 92(4):1650-8. PubMed ID: 8408618
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H.
    Vasc Health Risk Manag; 2012 Oct 15; 8():323-31. PubMed ID: 22661899
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R, Joy TR.
    Cardiovasc Ther; 2011 Oct 15; 29(5):327-39. PubMed ID: 20406242
    [Abstract] [Full Text] [Related]

  • 17. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
    Simic B, Mocharla P, Crucet M, Osto E, Kratzer A, Stivala S, Kühnast S, Speer T, Doycheva P, Princen HM, van der Hoorn JW, Jukema JW, Giral H, Tailleux A, Landmesser U, Staels B, Lüscher TF.
    Atherosclerosis; 2017 Feb 15; 257():186-194. PubMed ID: 28152406
    [Abstract] [Full Text] [Related]

  • 18. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F, Thieblemont Q, Muzotte E, Burr N, Urbain I, Sulpice T, Johns DG.
    Eur J Pharmacol; 2014 Oct 05; 740():135-43. PubMed ID: 25008069
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.